Company Filing History:
5 out of 249 
3 out of 2,538 
3 out of 3 
Years Active: 1999-2023
Title: Exploring the Innovations of Jeffrey Bruce Smaill in Hyperproliferative Disorders
Introduction:
Jeffrey Bruce Smaill, a distinguished inventor based in Auckland, NZ, has made significant contributions in the field of hyperproliferative disorders. With 14 patents to his name, Smaill's groundbreaking work focuses on developing prodrug compounds activated by AKR1C3 and FGFR kinase inhibitors for the treatment of various hyperproliferative diseases, including cancer.
Latest Patents:
Smaill's latest patents revolve around two significant innovations. The first is the development of prodrug compounds activated by AKR1C3 enzyme (AKR1C3-activated prodrugs). These compounds have exhibited the ability to penetrate neoplasm tissue and selectively eliminate AKR1C3-expressing target cells responsible for hyperproliferative disorders such as cancer. This groundbreaking approach offers promising avenues for effective cancer treatment.
The second innovation centers around FGFR kinase inhibitors and their pharmaceutical applications. Smaill's research focuses on developing compounds and prodrugs that inhibit Fibroblast Growth Factor Receptor kinase activity. These inhibitors have shown potential in treating a wide range of hyperproliferative diseases, including retinopathy, psoriasis, rheumatoid arthritis, and tumour metastasis, among others.
Career Highlights:
Throughout his career, Jeffrey Bruce Smaill has collaborated with prestigious organizations to bring his innovative ideas to life. One such collaboration was with Auckland Uniservices Limited, a knowledge transfer company that bridges the gap between academia and industry. Smaill's association with this organization likely facilitated the development and commercialization of his patents.
Smaill has also worked with Warner-Lambert Company, an esteemed pharmaceutical company renowned for its contributions to the healthcare industry. Collaborating with this company further showcased Smaill's talents in the field of hyperproliferative disorder research.
Collaborations:
In his journey as an inventor, Jeffrey Bruce Smaill has had the privilege of collaborating with accomplished individuals in his field. Notable among his coworkers are Adam Vorn Patterson and Amir Ashoorzadeh, whose expertise likely contributed to the successful realization of his patents. Their collaborative efforts have pushed the boundaries of medical science and paved the way for potential breakthroughs in treating hyperproliferative disorders.
Conclusion:
Jeffrey Bruce Smaill's pioneering work in developing prodrug compounds activated by AKR1C3 enzyme and FGFR kinase inhibitors represents significant advancements in the treatment of hyperproliferative disorders such as cancer. Through his research, Smaill has demonstrated a deep understanding of biology and pharmaceutical applications, setting the stage for groundbreaking therapeutic interventions. As the medical field continues to evolve, Smaill's contributions will undoubtedly play a crucial role in shaping the future of healthcare innovations.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.